What are the latest guidelines for restarting antiplatelet therapy (low‑dose aspirin [acetylsalicylic acid] and clopidogrel [Plavix]) after an intracerebral hemorrhage?

Restarting Antiplatelet Therapy After Intracerebral Hemorrhage

Antiplatelet therapy (aspirin or clopidogrel) may be considered and is reasonable to restart after intracerebral hemorrhage (ICH) in patients who were previously taking these medications for secondary prevention of cardiovascular events, as current evidence suggests it does not significantly increase the risk of recurrent ICH. 1

Current Guideline Recommendations

The 2023 American Heart Association/American Stroke Association focused update provides Level B evidence supporting antiplatelet resumption after ICH 1. This recommendation is based primarily on the RESTART trial, which demonstrated that antiplatelet agents might actually be protective rather than harmful after ICH associated with antithrombotic use.

Key Evidence from RESTART Trial

The RESTART trial (537 ICH survivors followed for median 3.0 years) showed counterintuitive findings 1, 2:

• Recurrent ICH rate: 8.2% with antiplatelet therapy vs. 9.3% without (adjusted HR 0.87,95% CI 0.49-1.55)
• Major vascular events: 26.8% with antiplatelet vs. 32.5% without (HR 0.79,95% CI 0.58-1.08)
• The trial suggests antiplatelet therapy does not increase recurrent ICH risk and may reduce overall cardiovascular events

Timing of Antiplatelet Resumption

Early resumption (within 30 days) appears as safe as delayed resumption (31-365 days) based on real-world data 3:

• 1-year recurrent ICH risk: 3.12% (early) vs. 3.27% (late), adjusted HR 0.967
• Similar risks for all-cause mortality, major hemorrhagic events, and ischemic stroke

Specific Patient Populations That May Benefit More from Early Resumption:

• Patients without prior cerebrovascular disease: Lower all-cause mortality (AHR 0.199) and major hemorrhagic events (AHR 0.090) 3
• Patients with chronic kidney disease: Lower ischemic stroke risk (AHR 0.065) 3

Clinical Decision-Making Algorithm

Step 1: Assess Indication Strength

Restart antiplatelet therapy if the patient has:

• Previous ischemic stroke or TIA
• Established coronary artery disease
• Peripheral arterial disease
• High cardiovascular risk requiring secondary prevention

Step 2: Verify Contraindications

Do NOT restart if 4:

• Active pathological bleeding
• Intracranial hemorrhage is still evolving or unstable
• Patient has hypersensitivity to the antiplatelet agent

Step 3: Timing Considerations

• Optimal window: Consider restarting within 30 days after ICH if hemostasis is achieved 3
• Ensure follow-up imaging confirms stability of hemorrhage
• Resume as soon as hemostasis is documented 4

Step 4: Agent Selection

• Continue the same antiplatelet agent (aspirin or clopidogrel) that was used pre-ICH
• Aspirin: 75-325 mg daily 4
• Clopidogrel: 75 mg daily without loading dose 4

Important Caveats and Pitfalls

Common Pitfalls to Avoid:

1. Indefinite avoidance of antiplatelets: This increases cardiovascular event risk without proven benefit in reducing recurrent ICH 2
2. Using loading doses: Avoid clopidogrel loading doses after ICH; use maintenance dosing only 4
3. Premature resumption: Ensure hemostasis is achieved before restarting 4

Special Considerations:

• Dual antiplatelet therapy: Not recommended after ICH; use single agent only
• Concomitant medications: Avoid omeprazole/esomeprazole with clopidogrel (reduces antiplatelet effect) 4
• Monitoring: Watch for signs of bleeding, particularly gastrointestinal and at puncture sites 4

Current Practice Patterns

Real-world data shows significant underutilization 5:

• Only 10.4% of ICH survivors receive antiplatelet therapy at discharge
• Only 16.6% of patients with pre-ICH antiplatelet use have therapy restarted
• This conservative approach may expose patients to unnecessary cardiovascular risk

Ongoing Research

The ASPIRING trial (targeting 4,148 participants) is underway to provide definitive evidence on antiplatelet effects after ICH across various subgroups 1. Until these results are available, current evidence supports cautious resumption in appropriate candidates.

The balance has shifted: The traditional fear of recurrent ICH with antiplatelet resumption is not supported by current evidence, while the cardiovascular risk of withholding therapy remains substantial.